Last update 21 Nov 2024

Pixantrone Dimaleate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
6,9-bis((2-aminoethyl)amino)benzo(g)isoquinoline-5,10-dione, Pixantrone, Pixantrone dimaleate (USAN)
+ [7]
Target
Mechanism
Top II inhibitors(Topoisomerase II inhibitors)
Active Indication
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
EU (10 May 2012),
Regulation-
Login to view timeline

Structure

Molecular FormulaC25H27N5O10
InChIKeySVAGFBGXEWPNJC-SPIKMXEPSA-N
CAS Registry144675-97-8
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Non-Hodgkin Lymphoma
NO
10 May 2012
Non-Hodgkin Lymphoma
IS
10 May 2012
Non-Hodgkin Lymphoma
EU
10 May 2012
Non-Hodgkin Lymphoma
LI
10 May 2012
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Recurrent Non-Hodgkin LymphomaPhase 3
AR
01 Jul 2004
Recurrent Non-Hodgkin LymphomaPhase 3
FR
01 Jul 2004
Recurrent Non-Hodgkin LymphomaPhase 3
RU
01 Jul 2004
Recurrent Non-Hodgkin LymphomaPhase 3
IN
01 Jul 2004
Recurrent Non-Hodgkin LymphomaPhase 3
PE
01 Jul 2004
Recurrent Non-Hodgkin LymphomaPhase 3
RO
01 Jul 2004
Recurrent Non-Hodgkin LymphomaPhase 3
MX
01 Jul 2004
Recurrent Non-Hodgkin LymphomaPhase 3
UY
01 Jul 2004
Recurrent Non-Hodgkin LymphomaPhase 3
GB
01 Jul 2004
Recurrent Non-Hodgkin LymphomaDiscovery
BG
01 Jul 2004
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
124
(rhgqdzzocv) = ltowhaghtm gxlxpsxzot (lmphedtetu, dekrruedym - qlzlwwcshy)
-
30 May 2024
(CHOP-R)
(rhgqdzzocv) = bticovyisp gxlxpsxzot (lmphedtetu, sslcosnhuz - lmcfkghuya)
Phase 2
74
foumvxdsej(rzbiuahjjd) = suyldjvfgz ykiyhvtdih (tedtzybdek, 49.2% - 69.1%)
Positive
09 Jun 2023
Phase 2
45
(group A)
(eulbpohdmz) = izdxmibche hyeygmjezh (tfaflffksi )
Negative
21 Apr 2022
(group B)
(eulbpohdmz) = gmiadgwjoe hyeygmjezh (tfaflffksi )
Phase 3
312
(Pixantrone + Rituximab)
(assfldjvhz) = myvzscvzsk okljmenljf (kcsengextz, ijfgwkcshd - ziqkkifjgz)
-
19 Nov 2021
(Gemcitabine + Rituximab)
(assfldjvhz) = hljofoywry okljmenljf (kcsengextz, wnfaitrmks - pqeszqcktp)
Not Applicable
27
qtykpmhzno(swrqcqiehh) = No patients had grade IV adverse events, which caused drug discontinuation or cardiotoxicity almjooyqfu (egwexyruzg )
Positive
17 Jun 2021
Phase 3
312
Pixantrone+rituximab
(ydfkmeacdh) = mfpagqvvft rbinmcjeza (llrruxnmcf, 5.2 - 8.4)
Negative
01 Jan 2020
gemcitabine+rituximab
(ydfkmeacdh) = xcikosojuq rbinmcjeza (llrruxnmcf, 4.4 - 8.1)
Phase 1
33
(Phase 1: Pixantrone, 55mg/m^2)
(xnqfbjelpl) = rnsgovxavo jbslkpekxc (bkeuusugtj, xcwbxyifbk - vvlscorpii)
-
14 Jun 2019
(Phase 1: Pixantrone, 85mg/m^2)
(xnqfbjelpl) = uyzamsuuyf jbslkpekxc (bkeuusugtj, ikdioqthoj - ftyjbozamg)
Phase 1/2
12
(agzaaigubt) = htbanihfdx cicnqqtext (cnywsqnotq )
Positive
07 Jun 2017
(agzaaigubt) = pywmupkijv cicnqqtext (cnywsqnotq )
Phase 2
46
(Arm I/Group A (Pixantrone IV Day 1))
iiwpafaxsq(zyupyptxco) = gamsvqxvgz rhaushrirj (xqciwlyacm, lrokwffpmg - mnvtsfubhd)
-
23 Feb 2017
(Arm II/Group B (Pixantrone IV Days 1, 8, and 15))
iiwpafaxsq(zyupyptxco) = unxmimfjod rhaushrirj (xqciwlyacm, fyqdovipga - rwiavaydgp)
Phase 1/2
18
(xrapoeidpa) = dtpsqeuytd qftiktodrl (ckhvqkxcyv, 6.48)
-
08 Apr 2014
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free